Collectively, our results demonstrate that although CARD14-induced proteolytic activity of MALT1 does not regulate survival of LNCaP cells, constitutive activation of MALT1 contributes to the production of several cancer-related proteins, highlighting the potential of pharmacological inhibition of MALT1 as a novel therapeutic strategy for PCa. Here, MALT1 is linked to posterior cortical atrophy.